HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Behr, T. M. Articles by Goldenberg, D. M. Search for Related Content PubMed PubMed Citation Articles by Behr, T. M. Articles by Goldenberg, D. M.

Reduction of Renal Uptake of Monoclonal Antibody Fragments by Amino Acid Infusion

Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Newark, New Jersey
Department of Nuclear Medicine of the Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany

Correspondence: For correspondence or reprints contact: David M. Goldenberg, ScD, MD, Garden State Cancer Center at the Center for Molecular Medicine and Immunology, 1 Bruce St., Newark, NJ 07103-2763.

ABSTRACT

The renal uptake of radiolabeled antibody fragments and peptides presents a problem in radioimmunodetection and therapy, compromising lesion sensitivity, especially with intracellularly-retained isotopes. Previously, we showed that cationic amino acids and their derivatives are capable of significantly reducing kidney uptake in animals (1–4). We report our initial clinical results of successful renal uptake reduction in five patients who underwent cancer radioimmunodetection with ^99mTc-anti-CEA Fab' fragments. Methods: The patients were infused with two liters of a commercially-available nutritive amino acid solution (containing approximately 2.25 g/liter lysine-glutamate and 2.50 g/liter arginine), whereas 75 control patients received the same volume of saline (quantification of organ and tumor kinetics from conjugate whole-body views by ROI technique). Results: The renal uptake in the amino acid group was significantly lower (p < 0.05) than in the control group (11.1 ± 2.0% injected dose versus 17.7 ± 7.0% injected dose at 24 hr postinjection), whereas the uptake of all other organs remained unaffected. Gel filtration chromatography of the urine taken from amino-acid-treated patients showed that a significantly higher amount of excreted activity was bound to intact Fab' (53% of excreted activity) in contrast to only less than 10% in the control group. Conclusion: The renal uptake of monoclonal antibody fragments in patients can be reduced significantly by amino acid infusion, even at considerably lower doses than those that were safe and effective in animals. As was found in animals, the mechanism seems to rely on an inhibition of the re-absorption of tubularly-filtered proteins by the proximal tubule cells. These results encourage further clinical trials to lower the renal uptake experienced in radioimmunodetection, as well as in therapeutic trials with antibody fragments and peptides.

Key Words: monoclonal antibodies • Fab' fragments • renal uptake reduction • cationic amino acids

This article has been cited by other articles:

				E. Dadachova, R. A. Bryan, X. Huang, G. Ortiz, T. Moadel, and A. Casadevall Comparative Evaluation of Capsular Polysaccharide-Specific IgM and IgG Antibodies and F(ab')2 and Fab Fragments as Delivery Vehicles for Radioimmunotherapy of Fungal Infection Clin. Cancer Res., September 15, 2007; 13(18): 5629s - 5635s. [Abstract] [Full Text] [PDF]

				D. Moosmayer, D. Berndorff, C.-H. Chang, R. M. Sharkey, A. Rother, S. Borkowski, E. A. Rossi, W. J. McBride, T. M. Cardillo, D. M. Goldenberg, et al. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors. Clin. Cancer Res., September 15, 2006; 12(18): 5587 - 5595. [Abstract] [Full Text] [PDF]

				E. Vegt, J. F.M. Wetzels, F. G.M. Russel, R. Masereeuw, O. C. Boerman, J. E. van Eerd, F. H.M. Corstens, and W. J.G. Oyen Renal Uptake of Radiolabeled Octreotide in Human Subjects Is Efficiently Inhibited by Succinylated Gelatin J. Nucl. Med., March 1, 2006; 47(3): 432 - 436. [Abstract] [Full Text] [PDF]

				H. Karacay, P.-Y. Brard, R. M. Sharkey, C.-H. Chang, E. A. Rossi, W. J. McBride, D. R. Ragland, I. D. Horak, and D. M. Goldenberg Therapeutic Advantage of Pretargeted Radioimmunotherapy Using a Recombinant Bispecific Antibody in a Human Colon Cancer Xenograft Clin. Cancer Res., November 1, 2005; 11(21): 7879 - 7885. [Abstract] [Full Text] [PDF]

				M. Behe, G. Kluge, W. Becker, M. Gotthardt, and T. M. Behr Use of Polyglutamic Acids to Reduce Uptake of Radiometal-Labeled Minigastrin in the Kidneys J. Nucl. Med., June 1, 2005; 46(6): 1012 - 1015. [Abstract] [Full Text] [PDF]

				S. Froidevaux, M. Calame-Christe, H. Tanner, and A. N. Eberle Melanoma Targeting with DOTA-{alpha}-Melanocyte-Stimulating Hormone Analogs: Structural Parameters Affecting Tumor Uptake and Kidney Uptake J. Nucl. Med., May 1, 2005; 46(5): 887 - 895. [Abstract] [Full Text] [PDF]

				E. Dadachova, J. D. Nosanchuk, L. Shi, A. D. Schweitzer, A. Frenkel, J. S. Nosanchuk, and A. Casadevall Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin PNAS, October 12, 2004; 101(41): 14865 - 14870. [Abstract] [Full Text] [PDF]

				R. Barone, S. Pauwels, J. De Camps, E. P. Krenning, L. K. Kvols, M. C. Smith, H. Bouterfa, O. Devuyst, and F. Jamar Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2275 - 2281. [Abstract] [Full Text] [PDF]

				S. Gratz, H. J.J.M. Rennen, O. C. Boerman, W. J.G. Oyen, and F. H.M. Corstens Rapid Imaging of Experimental Colitis with 99mTc-Interleukin-8 in Rabbits J. Nucl. Med., June 1, 2001; 42(6): 917 - 923. [Abstract] [Full Text] [PDF]

				N. Kang, S. Hamilton, J. Odili, G. Wilson, and J. Kupsch In Vivo Targeting of Malignant Melanoma by 125Iodine- and 99mTechnetium-labeled Single-chain Fv Fragments against High Molecular Weight Melanoma-associated Antigen Clin. Cancer Res., December 1, 2000; 6(12): 4921 - 4931. [Abstract] [Full Text]

				S. Froidevaux, A. Heppeler, A. N. Eberle, A.-M. Meier, M. Hausler, C. Beglinger, M. Behe, P. Powell, and H. R. Macke Preclinical Comparison in AR4-2J Tumor-Bearing Mice of Four Radiolabeled 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Somatostatin Analogs for Tumor Diagnosis and Internal Radiotherapy Endocrinology, September 1, 2000; 141(9): 3304 - 3312. [Abstract] [Full Text] [PDF]

				Y. Arano, Y. Fujioka, H. Akizawa, M. Ono, T. Uehara, K. Wakisaka, M. Nakayama, H. Sakahara, J. Konishi, and H. Saji Chemical Design of Radiolabeled Antibody Fragments for Low Renal Radioactivity Levels Cancer Res., January 1, 1999; 59(1): 128 - 134. [Abstract] [Full Text] [PDF]

				H. Kobayashi, N. Le, I.-s. Kim, M.-K. Kim, J.-E. Pie, D. Drumm, D. S. Paik, T. A. Waldmann, C. H. Paik, and J. A. Carrasquillo The Pharmacokinetic Characteristics of Glycolated Humanized Anti-Tac Fabs Are Determined by Their Isoelectric Points Cancer Res., January 1, 1999; 59(2): 422 - 430. [Abstract] [Full Text] [PDF]

				J. W. Proksch, W. B. Gentry, and S. M. Owens Pharmacokinetic Mechanisms for Obtaining High Renal Coelimination of Phencyclidine and a Monoclonal Antiphencyclidine Antigen-Binding Fragment of Immunoglobulin G in the Rat J. Pharmacol. Exp. Ther., November 1, 1998; 287(2): 616 - 624. [Abstract] [Full Text]